Related Experiment Videos
[Intravenous clomipramine for depressive disorders]
Jerzy Landowski1, Ewa Lamparska, Hubert Wichowicz
1I Klinika Chorób Psychicznych AM w Gdańsku.
Psychiatria Polska
|March 22, 2003
Summary
Intravenous clomipramine infusions effectively treated patients with depressive episodes, including recurrent depressive disorder and bipolar affective disorder. This therapy demonstrated significant clinical improvement and was well-tolerated by participants.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Context:
- Depressive episodes significantly impact patient well-being and quality of life.
- Recurrent depressive disorder and bipolar affective disorder are common psychiatric conditions requiring effective treatment.
- Intravenous administration offers a potential route for rapid therapeutic drug delivery.
Purpose:
- To evaluate the efficacy and tolerability of clomipramine intravenous infusions in patients experiencing depressive episodes.
- To assess clinical improvement using the Clinical Global Impression (CGI) scale.
- To determine the optimal dosage and treatment duration for this therapeutic approach.
Summary:
- Fifty-one patients with depressive episodes (40 with recurrent depressive disorder, 11 with bipolar affective disorder) received clomipramine intravenous infusions.
- Treatment involved 5 to 21 infusions, with a median maximum dose of 150 mg.
- Significant clinical improvement was observed, as measured by the CGI scale, with the therapy being well-tolerated.
Impact:
- Intravenous clomipramine shows promise as an effective treatment for severe depressive episodes.
- The findings support further investigation into intravenous clomipramine for mood disorders.
- This therapeutic strategy offers a potentially valuable option for treatment-resistant depression.